

Curriculum Vitae

Univ.-Prof. Dr. med. H. Wiendl

Ad Personam

Name Prof. Prof. h.c. Heinz Wiendl, MD, * 07.05.1968, male
Nationality German
Address University Hospital Münster
 Department of Neurology
 Albert-Schweitzer-Campus 1, Building A1
 48149 Münster
 Germany
 Phone: +49 (0) 251 83 46 810
 E-Mail: heinz.wiendl@ukmuenster.de
Position Professor, Chair

Academic Education

1997 Approbation
 1989-1996 Medicine, Universities of Erlangen, Basel, Duke

Scientific Degrees

2004 Habilitation treatise: „Immune regulatory role of the muscle: Implications for the immune pathogenesis of inflammatory myopathies“
 1996 conferring of a doctorate (MD)

Appointments

2013 Professor and Chair, Department of Neurology, University of Muenster, Germany
 2010 Professor and Chair, Department of Inflammatory Diseases of the Nervous System and Neurooncology, University of Muenster, Germany
 2005-2010 Professor of Neurology, Head of Clinical Research Group for Multiple Sclerosis and Neuroimmunology, Department of Neurology, University of Wuerzburg)
 2004 Head of a junior research group for neuroimmunology, Interdisciplinary Centre for Clinical Research in Tuebingen, Germany
 2000-2004 Clinical and research fellow in the Hertie Institute for Brain Research, Department of Neurology, University of Tuebingen
 1998-2000 Scholarship granted by the Deutsche Forschungsgemeinschaft (DFG) at the Max Planck-Institute for Neurobiology, department of neuroimmunology, Martinsried (*Prof. H. Wekerle, MD; Prof. R. Hohlfeld, MD*)
 1997-1998 Research fellow at the Institute of Anatomy and Neuro-Anatomy II of the University of Erlangen-Nuremberg
 1996-1997 Residency program at the Department of Neurology of the University of Erlangen-Nuremberg

Calls, appointments, offers

1. C3 professorship University of Wuerzburg, Germany (primo loco) 2004 (accepted)
2. W3 professorship of the Schilling foundation (W3), Institute of Neuroimmunology, 2009 (not accepted)
3. W3 professorship for neuroinflammation, University of Muenster (primo loco) 2009 (accepted)
4. W3 professorship for neurology, Department of Neurology, Mainz (secundo loco)
5. W3 professorship for neurology, Chair, Department of Neurology, Regensburg (primo loco, not accepted)

Publications Neurology – examples from the last years

1. Gerwien H*, Hermann S, Zhang X, Korpos E, Song J, Kopka K, Faust A, Wenning C, Gross CC, Honold L, Melzer M, Opdenakker G, **Wiendl H**, Schäfers M*, Sorokin L.* Imaging Matrix Metalloproteinase Activity in Multiple Sclerosis as a Specific Marker of Leukocyte Penetration of the Blood-Brain Barrier. *Sci Transl Med*. 2016;8(364):364ra152.
2. Klotz L, Kuzmanov I, Hucke S, Gross CC, Posevitz V, Dreykluft A, Schulte-Mecklenbeck A, Janoschka C, Lindner M, Herold M, Schwab N, Ludwig-Portugall I, Kurts C, Meuth SG, Kuhlmann T, Wiendl H. B7-H1 shapes T-cell-mediated brain endothelial cell dysfunction and regional encephalitogenicity in spontaneous CNS autoimmunity. *Proc Natl Acad Sci U S A*. 2016;113(41):E6182-E6191.
3. Gross CC, Schulte-Mecklenbeck A, Rünzi A, Kuhlmann T, Posevitz-Fejfar A, Schwab N, Schneider-Hohendorf T, Herich S, Held K, Konjević M, Hartwig M, Dornmair K, Hohlfeld R, Ziemssen T, Klotz L, Meuth SG, **Wiendl H**. Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation. *Proc Natl Acad Sci U S A*. 2016;113(21):E2973-82.
4. Kappos L, Wiendl H, Selmaj K, Arnold DL, Havrdova E, Boyko A, Kaufman M, Rose J, Greenberg S, Sweetser M, Riestler K, O'Neill G, Elkins J. Daclizumab HYP versus Interferon Beta-1a in Relapsing Multiple Sclerosis. *N Engl J Med*. 2015;373(15):1418-28.
5. Schneider-Hohendorf T, Rossaint J, Mohan H, Böning D, Breuer J, Kuhlmann T, Gross CC, Flanagan K, **Sorokin L**, Vestweber D, Zarbock A, Schwab N, **Wiendl H**. VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of T(H)17 cells. *J Exp Med*. 2014;211:1833-46
6. Breuer J, Schwab N, Schneider-Hohendorf T, Marziniak M, Mohan H, Bhatia U, Gross CC, Clausen BE, Weishaupt C, Luger TA, Meuth SG, Loser K, **Wiendl H**. Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity. *Ann Neurol*. 2014;75:739-58
7. Bittner S*, Ruck T*, Schuhmann MK, Herrmann AM, Maati HMO, Bobak N, Göbel K, Langhauser F, Stegner D, Ehling P, Borsotto M, Pape H, Nieswandt B, Kleinschnitz C, Heurteaux C, Galla H, Budde T, **Wiendl H***, Meuth SG*. Endothelial TWIK-related potassium channel-1 (TREK 1) regulates immune-cell trafficking into the CNS. *Nat Med*. 2013;19:1161-5 *equal contribution
8. Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S, Brochet B, Vermersch P, Lebrun-Frenay C, Posevitz-Fejfar A, Capra R, Imberti L, Straeten V, Haas J, Wildemann B, Havla J, Kümpfel T, Meinl I, Niessen K, Gölz S, Kleinschnitz C, Warnke C, Buck D, Gold R, Kieseier BC, Meuth SG, Foley J, Chan A, Brassat D, **Wiendl H**. L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. *Neurology*. 2013;81:865-71
9. Kleinschnitz C, Kraft P, Dreykluft A, Hagedorn I, Gobel K, Schuhmann MK, Langhauser F, Helluy X, Schwarz T, Bittner S, Mayer CT, Brede M, Varallyay C, Pham M, Bendszus M, Jakob P, Magnus T, Meuth SG, Iwakura Y, Zerneck A, Sparwasser T, Nieswandt B, Stoll G, **Wiendl H**. Regulatory T cells are strong promoters of acute ischemic stroke in mice by inducing dysfunction of the cerebral microvasculature. *Blood*. 2013;121:679-91
10. Huang Y, Zozulya AL, Weidenfeller C, Metz I, Buck D, Toyka KV, Brück W, **Wiendl H**. Specific central nervous system recruitment of HLA-G+ regulatory T cells in multiple sclerosis. *Ann Neurol*. 2009;66:171-83

Since 1998 more than 350 peer reviewed publications
 (<http://www.ncbi.nlm.nih.gov/pubmed/?term=Wiendl+H>), e.g. *Nature Medicine*, *Journal of Experimental Medicine*, *Blood*, *Annals of Neurology*, *BRAIN*, *Neurology*, *Nature Neuroscience*, *Immunity*, 3 books (editor), several book chapters

*equal senior authorship+correspondence

Awards

2015	Sobek award for MS research of the German Society for Multiple Sclerosis (DMSG)
2009	Heinrich Pette award of the German Society for Neurology (DGN)
2004	Sobek award for MS research (young scientists' award) of the DMSG
2003	Felix-Jerusalem award of the German Society for Muscular Diseases (DGM)

Special recognitions

2017-	Honorary Professor of the Sydney Medical School
2016-	Member of the International Society of Neurosciences' (ISNI) International Advisory Board
2016-	Member of the Expert's Committee on Neurosciences of the German Research Foundation (DFG)
2016-	Member of the ISNI
2016-	Representative of the Academia in the Board of directors of the University Hospital Muenster (UKM)
2016-	Speaker of the DFG funded transregional co-operative research centre (TR-CRC) "Multiple Sclerosis" (evaluated 03/2016)
2016-	Expert Committee for cellular neurosciences at the DFG
2016-	Representative of the academia in the supervisory board of the UKM
2013-	Executive Board Member, Felgenhauer Foundation for young Neuroscientists
2013-2016	Dean for Research and Young Scientists of the medical faculty Muenster
2012-	Co-Spokesperson TR-CRC 128 "Multiple Sclerosis" (Rhine-Main, Muenster, Munich) (funded by the DFG)
2012-	Principal investigator and member of the steering committee member of the cluster of excellence "Cells in Motion" (CiM), Muenster (funded by the DFG)
2012-2014	Board member of the Interdisciplinary Centre for Clinical Research (IZKF) Muenster
2011-	Executive Board member of the German society for Neurologists (BDN)
2009-2013	Spokesperson, National German Competence Network of Multiple sclerosis (BMBF-funded)
2010-	Member: Drug Commission of the German Medical Association
2008, 2014	Coordinator: Therapeutic guidelines of the German Society for Neurology: myositis, myasthenia gravis
2008	Member of reviewers committee "Autoimmune Centers of Excellence" for the National Institutes of Health (NIH)
2004-	Scientific Advisory Committee for the International Conferences on HLA-G
2001, 2012, 2014	Member of the Multiple Sclerosis Therapy Consensus Group (MSTCG)

Reviewer for scientific journals (examples)

Annals of Neurology, Blood, Brain, Journal of Immunology, FASEB Journal, Human Immunology, International Journal of Cancer, JAMA, JAMA Neurology, Journal of Clinical Investigations, Journal of Experimental Medicine, Journal of Immunology, Journal of Neurochemistry, Journal of Neuroimmunology, Journal of Neuroinflammation, Lancet, Lancet Neurology, Nature Medicine, Neurology, New England Journal of Medicine, Trends in Immunology,

Reviewer for institutions (examples)

Academy of Sciences Finland, American Myositis Association, Association Française contre les Myopathies, Austrian Science Fund, Duchenne Parents Project (DPP), "Autoimmune Centers of Excellence" for the National Institutes of Health (NIH), Deutsche Forschungsgemeinschaft (DFG), Deutsche Multiple Sklerose Gesellschaft (DMSG), Medical Research Council (MRC) Wellcome Trust United Kingdom, Wilhelm Sander Stiftung, Alexander von Humboldt-Stiftung, MS Research Australia (MSRA), Multiple Sclerosis Society UK (MSS), Stiftung Rheinland-Pfalz für Innovation, National Institutes of Health (NIH), Fondation pour la Recherche Médicale

Member of editorial boards

Journal of Neuroinflammation, Neurotherapeutics, Recent Patents on Inflammation & Allergy Drug Discovery International Journal of Clinical Practice, Endocrine Metabolic Immune Disorders – Drug Targets,

PI/Co-ordination of clinical trials (examples)

Treosulfan in patients with secondary-progressive MS: Study coordinator, Principal Investigator,

- 1) *Treosulfan pilot study* 2001-2004, Study coordinator, generating the study protocol
- 2) *Treosulfan Phase II Study*, 2007-2008, principal investigator Germany, generating the study protocol, 2007-

DECIDE: principal investigator (05/2010-)

ToFingo: principal investigator (2011, 2014)

EXPAND: principal investigator (09/2012-)

TeriDynamic: principal investigator (02/2013-09/2014)

ALAIN: principle investigator (02/2015-)

Total: ≥ 30 phase I-IV trials, including IITs as principal investigator, member of several steering committees (e.g. IL17 program, IL2R blockade program)

Funding

European Union, the German Ministry of Education and Research (BMBF), the North-Rhine Westphalian Ministry of Education and Research, The German Research Foundation (DFG), the European Union (EU), the Program for "Innovative Medical Research" (IMF) Muenster, the Interdisciplinary Center for Clinical Research (IZKF) Muenster, The Hertie Foundation, The Else Kroener Fresenius Foundation, the RE Children's Foundation, The Thyssen Foundation and industry; Ad personam: 13.5 Mio. €/last 5 years